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Amid intense media coverage, the Cochrane Collaboration this month published an 
updated systematic review on the efficacy of neuraminidase inhibitors (NAIs) for 
influenza.1 The authors identified 107 clinical study reports (CSRs) of published and 
unpublished randomized clinical trials (RCTs). Of these, less than half were included 
in the meta-analysis, which concluded that in adults oseltamivir reduced time to first 
alleviation of symptoms of influenza-like illness by 16·8 hours (95% confidence 
interval (CI) 8·4–25·1 hours, P<0·0001). In otherwise healthy children oseltamivir 
reduced illness by 29 hours (95% CI 12–47, P=0·001), but benefit was not evident in 
asthmatic children. Zanamivir cut symptom duration in adults by 0·60 days (CI 0·39–
0·81), P<0·00001), but it had no significant effect in children. For serious influenza-
related complications or those leading to study withdrawal, and radiologically-verified 
pneumonia, the available data did not reveal significant effects with either drug. 
There were no influenza-related deaths in the oseltamivir treatment trials and only 
two in the zanamivir treatment trials, as would be expected in community-based 
studies during seasonal outbreaks of influenza. Most patients in the included 
treatment studies were not at high risk of severe complications and the primary 
outcome in the vast majority of studies was time to alleviation of illness rather than 
morbidity and mortality outcomes relevant to pandemics or people with co-
morbidities.   
 
Despite incorporating extensive data from hitherto inaccessible CSRs, the new 
findings are little different from the first Cochrane review reported in 2000.2 The 
included trials were not designed to assess impact on life-threatening complications, 
and absence of a reliable signal from such underpowered RCTs does not imply 
absence of effect.  Nonetheless, the authors conclude, …“The treatment trials with 
oseltamivir or zanamivir do not settle the question of whether the complications of 
influenza (such as pneumonia) are reduced.” We agree, as the included RCTs were 
not appropriately designed or powered to assess impact on life-threatening 
complications. So, what are the implications of the review and of observational 
studies of NAIs in normal clinical practice?  Are the Cochrane authors correct in 
stating “there appears to be no evidence for patients, clinicians or policy-makers to 
use these drugs to prevent serious outcomes, both in annual influenza and pandemic 
influenza outbreaks”?  
 
In March 2014, a meta-analysis of observational Individual Participant Data (IPD) for 
29,234 patients hospitalised with A(H1N1)pdm09 virus infection worldwide reported a 
roughly one-fifth (OR=0·81 (95% CI 0·70–0·93)) reduction in mortality associated 
with NAI treatment compared to no treatment, irrespective of the timing of starting 
treatment; and a halving of the risk of death (OR=0·50, 95% CI 0·37–0·67, P<0·001) 
if treatment was started within 48 hours of symptom onset.3 These data from 
hospitalised patients during the 2009 A(H1N1) pandemic confirm the findings of 
multiple smaller observational studies of NAI treatment of hospitalized patients with 
seasonal, pandemic, or novel influenza A virus infections that have reported 
reductions in the risk of critical illness and death.4-7 These associations with reduced 
mortality risk were less pronounced and not significant in children,3 although other 
researchers have demonstrated significant reductions in mortality in children.8 Given 
that the 2009 A(H1N1) pandemic produced more than 200,000 respiratory-related 
deaths worldwide,9,10 the findings imply that many deaths were (and could have 
been) averted by NAI treatment, especially if instigated soon after illness onset. Of 
note, there was an increase in the mortality hazard rate with each days delay in 
initiation of treatment up to day five as compared with treatment initiated within two 
days of symptom onset.3 
 
The causative virus, A(H1N1)pdm09, remains in circulation worldwide as a seasonal 
influenza virus, and continues to cause severe illness and death. While observational 
studies have limitations and weaknesses compared to RCTs, they may nevertheless 
help inform clinical practice, especially when no data from suitably powered placebo-
controlled RCTs of NAI treatment in hospitalised influenza patients are available or 
planned. Given seasonal attack rates of <5% for symptomatic influenza confirmed by 
polymerase chain reaction (PCR),11 and similar influenza virus detection rate in 
patients with community-acquired pneumonia,12 RCTs that test NAIs for severe 
morbidity and mortality outcomes will be exceedingly challenging. Hence the 
consistency with which clinically meaningful benefits from observational studies of 
NAI treatment have been reported make such a body of evidence difficult for 
clinicians, policy makers, and ethical committees to ignore. Accordingly, we advocate 
early NAI treatment for those prone to severe disease and in those hospitalized with 
influenza, in line with national public health guidance. 
 
Regarding stockpiling of NAIs for pandemic deployment, the pandemic threat from 
emergent influenza A viruses such as A(H7N9) and A(H5N1) persists. Although 
these lack current person-to-person transmissibility, pandemic planners must 
consider all evidence and weigh this against the risks of inaction and the likely public 
outcry if potentially life-saving drugs are not available in the face of unpredictable, but 
potentially severe, future influenza outbreaks.  
 
To conclude, the findings of the Cochrane Collaboration and those from 
observational studies are not in conflict. They provide evidence on different 
outcomes, for different groups of patients and across different settings. What matters 
is being able to reduce risk, mitigate the complications of influenza and save lives. 
Neuraminidase inhibitors remain an essential part of our armamentarium to lessen 
the impact of influenza.   
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